GeoVax Announces Upcoming Presentations at Scientific Conferences
May 04, 2022 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
April 27, 2022 16:00 ET
|
GeoVax, Inc.
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a...
GeoVax Announces Issuance of Malaria Vaccine Patent
April 26, 2022 09:00 ET
|
GeoVax, Inc.
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update
April 19, 2022 09:00 ET
|
GeoVax, Inc.
Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
April 18, 2022 17:52 ET
|
GeoVax, Inc.
Singapore, April 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--In a release issued under the same headline on Monday, April 18th at 1:55 ET by GeoVax, Inc., please note that the release was...
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress
April 12, 2022 09:00 ET
|
GeoVax, Inc.
Company’s COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100%...
GeoVax Announces Issuance of Cancer Vaccine Patent
March 22, 2022 09:00 ET
|
GeoVax, Inc.
IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
March 21, 2022 09:00 ET
|
GeoVax, Inc.
Presentation to Focus on GEO-CM02 Being Developed as aUniversal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference
March 16, 2022 09:00 ET
|
GeoVax, Inc.
Chairman & CEO David Dodd to Present Corporate UpdateCSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD ATLANTA, GA , March 16, 2022 (GLOBE NEWSWIRE)...
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
March 14, 2022 09:00 ET
|
GeoVax, Inc.
Comparative Trial Against Pfizer/BioNTech Vaccine Among Immunocompromised PatientsBooster to Pfizer/BioNTech or Moderna Vaccines Among Healthy PatientsATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) --...